The haemotoxicity of azathioprine in repeat dose studies in the female CD-1 mouse

International Journal of Experimental Pathology

Volumn 89, Issue 2, 2008, Pages 138-158

  Molyneux, Gemma ^a,b,e   Gibson, Frances M ^a   Chen, Christabelle M ^b   Marway, Harpal K ^b   McKeag, Sean ^c,d   Mifsud, Charles V J ^b   Pilling, Andrew M ^c   Whayman, Matthew J ^d   Turton, John A ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c Pathology Department   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Azathioprine; Haemotoxicity; Mouse; Myelotoxicity; Toxicity

Indexed keywords

AZATHIOPRINE; CYTOKINE; FLT3 LIGAND; IMMUNOSUPPRESSIVE AGENT;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPSY; BLOOD TOXICITY; BONE MARROW; BONE MARROW DEPRESSION; BONE MARROW TOXICITY; BURST FORMING UNIT E; CELL COUNT; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; ERYTHROCYTE; ERYTHROID CELL; EXTRAMEDULLARY HEMATOPOIESIS; FEEDING; FEMALE; FEMUR; GRANULOCYTE; HEMATOLOGICAL PARAMETERS; HISTOLOGY; LIVER HYPERTROPHY; MONOCYTE; MOUSE; MOUSE STRAIN; NONHUMAN; PANCYTOPENIA; PRIORITY JOURNAL; REPEATED DRUG DOSE; SPLEEN; STEM CELL; THROMBOCYTOPENIA; THYMUS ATROPHY;

ANIMALS; APOPTOSIS; AZATHIOPRINE; BODY WEIGHT; BONE MARROW CELLS; COLONY-FORMING UNITS ASSAY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROID PROGENITOR CELLS; FEMALE; HEMATOPOIETIC STEM CELLS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED ICR; PANCYTOPENIA;

EID: 40549116691     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/j.1365-2613.2008.00575.x     Document Type: Article

References (98)

1. Aarbakke J., Janka-Schaub G., Elion G.B. (1997) Thiopurine biology and pharmacology. TiPS 18, 3 7.
2. Al-Uzri A., Yorgin P.D., Kling P.J. (2003) Anemia in children after transplantation: etiology and the effect of immunosuppressive therapy on erythropoiesis. Pediatr. Transplant. 7, 253 264.
3. Bacon B.R., Treuhaft W.H., Goodman A.M. (1981) Azathioprine-induced pancytopenia. Occurrence in two patients with connective-tissue diseases. Arch. Intern. Med. 141, 223 226.
4. Beale K.M., Altman D., Clemmons R.R., Bolon B. (1992) Systemic toxicosis associated with azathioprine administration in domestic cats. Am. J. Vet. Res. 53, 1236 1240.
5. Ben Ari Z., Mehta A., Lennard L., Burroughs A.K. (1995) Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J. Hepatol. 23, 351 354.
6. Bertho J.M., Demarquay C., Frick J. et al. (2001) Level of Flt3-ligand in plasma: a possible new bio-indicator for radiation-induced aplasia. Int. J. Radiat. Biol. 77, 703 712.
7. Black A.J., McLeod H.L., Capell H.A. et al. (1998) Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann. Intern. Med. 129, 716 718.
8. Blumenthal R.D., Lew W., Juweid M. (2000) Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy. Cancer 88, 333 343.
9. BNF (2004) British National Formulary. London : British Medical Association.
10. Borel J.F., Feurer C., Gubler H.U., Stahelin H. (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6, 468 475.
11. Bostrom B. Erdmann G. (1993) Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am. J. Pediatr. Hematol. Oncol. 15, 80 86.
12. Bottiger L.E. Rausing A. (1972) Pure red cell anaemia: immunosuppressive treatment. Ann. Intern. Med. 76, 593 597.
13. Burke D.A., Dixon M.F., Axon A.T. (1989) Ulcerative colitis: prolonged remission following azathioprine-induced pancytopenia. J. Clin. Gastroenterol. 11, 327 330.
14. Calne R.Y. (1960) The rejection of renal homografts. Inhibition in dogs by 6-mercaptopurine. Lancet 1, 417 418.
15. Calne R.Y. (1961) Inhibition of the rejection of renal homografts in dogs by purine analogues. Transplant. Bull. 28, 65 81.
16. Calne R. (2004) Cyclosporine as a milestone in immunosuppression. Transplant. Proc. 36, 13S 15S.
17. Calne R.Y., Alexandre G.P., Murray J.E. (1962) A study of the effects of drugs in prolonging survival of homologous renal transplants in dogs. Ann. N. Y. Acad. Sci. 99, 743 761.
18. Calne R.Y., White D.J., Rolles K., Smith D.P., Herbertson B.M. (1978) Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A. Lancet 1, 1183 1185.
19. Calne R.Y., Rolles K., White D.J. et al. (1979) Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 2, 1033 1036.
20. Charles River (2005) Charles River UK Limited, Margste, Kent, UK. Product information (Technical support). http://www.criver.com.
21. Chklovskaia E., Jansen W., Nissen C. et al. (1999) Mechanism of flt3 ligand expression in bone marrow failure: translocation from intracellular stores to the surface of T lymphocytes after chemotherapy-induced suppression of hematopoiesis. Blood 93, 2595 2604.
22. Colombel J.F., Ferrari N., Debuysere H. et al. (2000) Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118, 1025 1030.
23. Connell W.R., Kamm M.A., Ritchie J.K., Lennard-Jones J.E. (1993) Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34, 1081 1085.
24. Creemers G.J., Van Boven W.P., Lowenberg B., Van Der Heul C. (1993) Azathioprine-associated pure red cell aplasia. J. Intern. Med. 233, 85 87.
25. Cuffari C., Li D.Y., Mahoney J., Barnes Y., Bayless T.M. (2004) Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn's disease on AZA therapy. Dig. Dis. Sci. 49, 133 137.
26. De Waal E.J., Timmerman H.H., Dortant P.M., Kranjc M.A., Van Loveren H. (1995) Investigation of a screening battery for immunotoxicity of pharmaceuticals within a 28-day oral toxicity study using azathioprine and cyclosporin A as model compounds. Regul. Toxicol. Pharmacol. 21, 327 338.
27. DeClerck Y.A., Ettenger R.B., Ortega J.A., Pennisi A.J. (1980) Macrocytosis and pure RBC anemia caused by azathioprine. Am. J. Dis. Child. 134, 377 379.
28. DeLeve L.D., Wang X., Kuhlenkamp J.F., Kaplowitz N. (1996) Toxicity of azathioprine and monocrotaline in murine sinusoidal lining cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology 23, 589 599.
29. Dollery C. (1999) Therapeutic Drugs. Edinburgh : Churchill Livingstone.
30. Elion G.B. (1989) The purine path to chemotherapy. Science. 244, 41 47.
31. Elion G.B., Bieber S., Hitchins G.H. (1960) A summary of investigations with 2-amino-6-[(1-methyl-4-nitro-5-imidazolyl)thio]purine (B.W. 57-323) in animals. Cancer Chemother. Rep. 8, 36 43.
32. Elion G.B., Callahan S., Bieber S., Hitchings G.M., Rundles R.W. (1961) A summary of investigations with 6-[(1-methyl-4-nitro-5-imidazolyl)thio] purine (B.W. 57-322). Cancer Chemother. Rep. 14, 93 98.
33. Fairchild C.R., Maybaum J., Kennedy K.A. (1986) Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment. Biochem. Pharmacol. 35, 3533 3541.
34. Frankel H.H., Yamamoto R.S., Weisburger E.K., Weisburger J.H. (1970) Chronic toxicity of azathioprine and the effect of this immunosuppressant on liver tumor induction by the carcinogen N-hydroxy-N-2-fluorenylacetamide. Toxicol. Appl. Pharmacol. 17, 462 480.
35. Gibson F.M., Andrews C.M., Diamanti P. et al. (2003) A new model of busulphan-induced chronic bone marrow aplasia in the female BALB/c mouse. Int. J. Exp. Pathol. 84, 31 47.
36. Goodwin W.E., Kaufman J.J., Mims M.M. et al. (1963) Human renal transplantation. I. Clinical experiences with six cases of renal homotransplantation. J. Urol. 89, 13 24.
37. Gratwohl A., John L., Baldomero H. et al. (1998) FLT-3 ligand provides hematopoietic protection from total body irradiation in rabbits. Blood 92, 765 769.
38. Harlan (2005) Harlan UK Limited, Bicester, Oxon, UK. Product information (Technical support). http://www.harlan.com.
39. Hernandez J.S., Van Loon J.A., Otterness D.M., Weinshilboum R.M. (1990) Mouse thiopurine methyltranserase pharmacogenetics: correlation of immunoreactive protein and enzymatic activity. J. Pharmacol. Exp. Ther. 252, 658 673.
40. Hess F., Jerusalem C., Polak M. (1976) Azathioprine hepatotoxicity, direct complication or secondary effect in rat liver transplantation. Eur. Surg. Res. 8, 156 165.
41. Hildner K., Marker-Hermann E., Schlaak J.F. et al. (1998) Azathioprine, mycophenolate mofetil, and methotrexate specifically modulate cytokine production by T cells. Ann. N. Y. Acad. Sci. 859, 204 207.
42. Hohlfeld R., Michels M., Heininger K., Besinger U., Toyka K.V. (1988) Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 38, 258 261.
43. Home Office (1989) Code of Practice for the Housing and Care of Animals Used in Scientific Procedures. London : Her Majesty's Stationary Office.
44. Huchet A., Belkacemi Y., Frick J. et al. (2003) Plasma Flt-3 ligand concentration correlated with radiation-induced bone marrow damage during local fractionated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 57, 508 515.
45. Imamura N., Nakano M., Kawase A., Kawamura Y., Yokoro K. (1973) Synergistic action of N-nitrosobutylurea and azathioprine in induction of leukemia in C57BL mice. Gann 64, 493 498.
46. Jensen M.K. Huttel M.S. (1976) Assessment of the effect of azathioprine on human bone marrow cells in vivo, combining chromosome studies and the micronucleus test. Dan. Med. Bull. 23, 152 154.
47. Jeurissen M.E., Boerbooms A.M., Van De Putte L.B. (1988) Pancytopenia related to azathioprine in rheumatoid arthritis. Ann. Rheum. Dis. 47, 503 505.
48. Kader H.A., Wenner Jr. W.J., Telega G.W., Maller E.S., Baldassano R.N. (2000) Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J. Clin. Gastroenterol. 30, 409 413.
49. Kerstens P.J., Stolk J.N., Hilbrands L.B., van de Putte L.B., De Abreu R.A., Boerbooms A.M. (1993) 5-nucleotidase and azathioprine-related bone-marrow toxicity. Lancet 342, 1245 1246.
50. Kerstens P.J., Stolk J.N., De Abreu R.A., Lambooy L.H., van de Putte L.B., Boerbooms A.A. (1995) Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum. 38, 142 145.
51. Klippel J.H. Decker J.L. (1974) Relative macrocytosis in cyclophosphamide and azathioprine therapy. JAMA. 229, 180 181.
52. Lawson D.H., Lovatt G.E., Gurton C.S., Hennings R.C. (1984) Adverse effects of azathioprine. Adverse Drug React. Acute Poisoning Rev. 3, 161 171.
53. Lee A.U. Farrell G.C. (2001) Mechanisms of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury. J. Hepatol. 35, 756 764.
54. Leipold G., Schutz E., Haas P.J., Oellerich M. (1997) Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. Arthritis Rheum. 40, 1896 1898.
55. Lemley D.E., Delacy L.M., Seeff L.B., Ishak K.G., Nashel D.J. (1989) Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis. Ann. Rheum. Dis. 48, 342 346.
56. Lennard L. (1992) The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. 43, 329 339.
57. Lennard L., Rees C.A., Lilleyman J.S., Maddocks J.L. (1983) Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br. J. Clin. Pharmacol. 16, 359 363.
58. Lennard L., Van Loon J.A., Weinshilboum R.M. (1989) Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther. 46, 149 154.
59. Lennard L., Hale J.P., Lilleyman J.S. (1993) Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia. Br. J. Clin. Pharmacol. 36, 277 284.
60. Lyman S.D., Seaberg M., Hanna R. et al. (1995) Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Blood 86, 4091 4096.
61. Marino I.R. Doyle H.R. (1994) Conventional immunosuppressant drugs. In : Immunosuppressive Drugs. Developments in Anti-rejection Therapy (eds A.W. Thomsom, T.E. Starzl Boston : Little Brown, pp. 5 7.
62. MC (2003) Medicines Compendium. Epsom : Datapharm Communications.
63. McGovern D.P. Travis S.P. (2003) Thiopurine therapy: when to start and when to stop. Eur. J. Gastroenterol. Hepatol. 15, 219 223.
64. McGovern D.P., Travis S.P., Duley J., Shobowale-Bakreel M., Dalton H.R. (2002) Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 122, 838 839.
65. McGrath B.P., Ibels L.S., Raik E., Hargrave M.J. (1975) Erythroid toxicity of azathioprin. Macrocytosis and selective marrow hypoplasis. Q. J. Med. 44, 57 63.
66. Molyneux G., Gibson F.M., Marway H. et al. (2004) Myelotoxic effects of the immunosuppressant drug azathioprine (AZA) in the CD-1 mouse after repeat dose administration. Toxicology 202, 83.
67. Molyneux G., Gibson F.M., Gordon-Smith E.C. et al. (2005) The haemotoxicity of mitomycin in a repeat dose study in the female CD-1 mouse. Int. J. Exp. Pathol. 86, 415 430.
68. Molyneux G., Gibson F.M., Whayman M., Turton J.A. (2008) Serum FLT-3 ligand in a busulphan-induced model of chronic bone marrow hypoplasia in the female CD-1 mouse. Int. J. Exp. Pathol. 89, 159 170.
69. Murray J.E., Merrill J.P., Harrison J.H., Wilson R.E., Dammin G.J. (1963) Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N. Engl. J. Med. 268, 1315 1323.
70. Nicholls A.J. Davidson R.J. (1979) Development of macrocytosis during azathioprine therapy after renal transplantation. A correlation of renal function with MCV. Transplantation 27, 220 221.
71. Old C.W., Flannery E.P., Grogan T.M., Stone W.H., San Antonio R.P. (1978) Azathioprine-induced pure red blood cell aplasia. JAMA 240, 552 554.
72. Pandya B., Thomson W., Poulton K., Bruce I., Payne D., Qasim F. (2002) Azathioprine toxicity and thiopurine methyltransferase genotype in renal transplant patients. Transplant. Proc. 34, 1642 1645.
73. Philpott N.J., Scopes J., Marsh J.C., Gordon-Smith E.C., Gibson F.M. (1995) Increased apoptosis in aplastic anaemia bone marrow progenitor cells: possible pathophysiological significance. Exp. Hematol. 23, 1642 1648.
74. Philpott N.J., Turner A.J., Scopes J. et al. (1996) The use of 7-amino-actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood 87, 2244 2251.
75. Prat M., Demarquay C., Frick J., Thierry D., Gorin N.C., Bertho J.M. (2005) Radiation-induced increase in plasma Flt3 ligand concentration in mice: evidence for the implication of several cell types. Radiat. Res. 163, 408 417.
76. Present D.H., Meltzer S.J., Krumholz M.P., Wolke A., Korelitz B.I. (1989) 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann. Intern. Med. 111, 641 649.
77. Pruijt J.F., Haanen J.B., Hollander A.A., Den Ottolander G.J. (1996) Azathioprine-induced pure red-cell aplasia. Nephrol. Dial. Transplant. 11, 1371 1373.
78. Rinkardt N.E. Kruth S.A. (1996) Azathioprine-induced bone marrow toxicity in four dogs. Can. Vet. J. 37, 612 613.
79. Rundles R.W., Laszlo J., Itoga T., Hobson J.B., Garrison Jr. F.E. (1961) Clinical and hematologic study of 6[(1-methyl-4-nitro-5-imidazolyl)thio]-purine (B.W.57-322) and related compounds. Cancer Chemother. Rep. 14, 99 115.
80. Scerri L. (1999) Azathioprine in dermatology. An overview with special emphasis on its use in non-bullous inflammatory dermatoses. Rheuma. Derm. 53, 343 348.
81. Schwab M., Schaffeler E., Marx C. et al. (2002) Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 12, 429 436.
82. Schwartz R., Dameshek W. (1959) Drug-induced immunological tolerance. Nature 13, 1682 1683.
83. Schwartz R., Stack J., Dameshek W. (1958) Effect of 6-mercaptopurine on antibody production. Proc. Soc. Exp. Biol. Med. 99, 164 167.
84. Smith C.C., Archer G.E., Forster E.J., Lambert T.R., Rees R.W., Lynch A.M. (1999) Analysis of gene mutations and clastogenicity following short-term treatment with azathioprine in MutaMouse. Environ. Mol. Mutagen. 34, 131 139.
85. Smith H.W., Winstead C.J., Stank K.K., Halstead B.W., Wierda D. (2003) A predictive F344 rat immunotoxicology model: cellular parameters combined with humoral responses to NP-CγG and KLH. Toxicology 194, 129 145.
86. Stolk J.N., Boerbooms A.M., De Abreu R.A. et al. (1998) Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum. 41, 1858 1866.
87. Sudhir R.R., Rao S.K., Shanmugam M.P., Padmanabhan P. (2002) Bilateral macular hemorrhage caused by azathioprine-induced aplastic anemia in a corneal graft recipient. Cornea 21, 712 714.
88. Sweetman S.C. (2005) Martindale: The Complete Drug Reference, 34th edn. London : Pharmaceutical Press.
89. Tapner M.J., Jones B.E., Wu M.W., Farrell G.C. (2004) Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Role of xanthine oxidase and mitochondrial injury. J. Hepatol. 40, 454 463.
90. Thompson D.F. Gales M.A. (1996) Drug-induced pure red cell aplasia. Pharmacotherapy 16, 1002 1008.
91. + T lymphocytes. J. Clin. Invest. 111, 1133 1145.
92. Turton J.A., Sones W.R., Andrews C.M. et al. (2006) Further development of a model of chronic bone marrow aplasia in the busulphan-treated mouse. Int. J. Exp. Pathol. 87, 49 63.
93. Van Furth R., Gassmann A.E., Diesselhoff-Den Dulk M.M. (1975) The effect of azathioprine (Imuran) on the cell cycle of promonocytes and the production of monocytes in the bone marrow. J. Exp. Med. 141, 531 546.
94. Watanabe A., Hobara N., Tobe K., Endo H., Nagashima H. (1979) Biochemical and morphological study on hepatotoxicity of azathioprine in rat. Acta Med. Okayama 33, 5 14.
95. Weisburger E.K. (1977) Bioassay program for carcinogenic hazards of cancer chemotherapeutic agents. Cancer 40, 1935 1949.
96. Whisnant J.K. Pelkey J. (1982) Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities. Ann. Rheum. Dis. 41, S44 S47.
97. Wickramasinghe S.N., Dodsworth H., Rault R.M., Hulme B. (1974) Observations on the incidence and cause of macrocytosis in patients on azathioprine therapy following renal transplantation. Transplantation 18, 443 446.
98. Wodnar-Filipowicz A., Lyman S.D., Gratwohl A., Tichelli A., Speck B., Nissen C. (1996) Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Blood 88, 4493 4499.